Probing the origins, diagnosis and treatment of amyloid diseases using antibodies.

[en] The deposition of proteins in the form of amyloid fibrils is the characteristic feature of more than 20 medical conditions affecting the central nervous system or a variety of peripheral tissues. These disorders, which include Alzheimer's disease, the prion diseases and type II diabetes, are of enormous importance in the context of present-day human health and welfare. Extensive research is therefore being carried out to define the molecular details of the mechanism of the pathological conversion of amyloidogenic proteins from their soluble forms into fibrillar structures. This review focuses on recent studies that demonstrate the power of using antibodies or antibody fragments to probe the process of fibril formation, and discusses the emerging potential of these species as diagnostic and therapeutic agents.

Disciplines :

Biochemistry, biophysics & molecular biology

Author, co-author :

Dumoulin, Mireille ; Université de Liège - ULiège > Département des sciences de la vie > Enzymologie et repliement des protéines

Dobson, Christopher

Language :

English

Title :

Probing the origins, diagnosis and treatment of amyloid diseases using antibodies.

Publication date :

2004

Journal title :

Biochimie

ISSN :

0300-9084

eISSN :

1638-6183

Publisher :

Elsevier, Paris, France

Volume :

Pages :

589-600

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 15 September 2009

Statistics

Number of views

76 (2 by ULiège)

Number of downloads

322 (5 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

S.E. Radford, and C.M. Dobson From computer simulations to human disease: emerging themes in protein folding Cell. 97 1999 291 298
P. Tompa Intrinsically unstructured proteins Trends Biochem. Sci. 27 2002 527 533
R. Sitia, and I. Braakman Quality control in the endoplasmic reticulum protein factory Nature 426 2003 891 894
A.L. Goldberg Protein degradation and protection against misfolded or damaged proteins Nature 426 2003 895 899
C.M. Dobson Protein folding and misfolding Nature 426 2003 884 890
P.J. Thomas, B.H. Qu, and P.L. Pedersen Defective protein folding as a basis of human disease Trends Biochem. Sci. 20 1995 456 459
M. Stefani, and C.M. Dobson Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution J. Mol. Med. 81 2003 678 699
V.N. Uversky, and A.L. Fink Conformational constraints for amyloid fibrillation: the importance of being unfolded Biochim. Biophys. Acta 1698 2004 131 153
G. Merlini, and V. Bellotti Molecular mechanisms of amyloidosis New Engl. J. Med. 349 2003 583 596
V.W. DeLaGarza Pharmacologic treatment of Alzheimer's disease: an update Am. Fam. Phys. 68 2003 1365 1372
L.E. Hebert, P.A. Scherr, J.L. Bienias, D.A. Benett, and D.A. Evans Alzheimer disease in the US population: prevalence estimates using the 2000 census Arch. Neurol. 60 2003 1119 1122
J.I. Guijarro, M. Sunde, J.A. Jones, I.D. Campbell, and C.M. Dobson Amyloid fibril formation by an SH3 domain Proc. Natl. Acad. Sci. USA 95 1998 4224 4228
F. Chiti, P. Webster, N. Taddei, A. Clark, M. Stefani, and G. Ramponi Designing conditions for in vitro formation of amyloid protofilaments and fibrils Proc. Natl. Acad. Sci. USA 96 1999 3590 3594
S.V. Litvinovich, S.A. Brew, S. Aota, S.K. Akiyama, C. Haudenschild, and K.C. Ingham Formation of amyloid-like fibrils by self-association of a partially unfolded fibronectin type III module J. Mol. Biol. 280 1998 245 258
M. Bucciantini, E. Giannoni, F. Chiti, F. Baroni, L. Formigli, J. Zurdo, N. Taddei, G. Ramponi, C.M. Dobson, and M. Stefani Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases Nature 416 2002 507 511
C.M. Dobson The structural basis of protein folding and its links with human disease, Philos Trans. R. Soc. London B Biol. Sci. 356 2001 133 145
M. Sunde, and C. Blake The structure of amyloid fibrils by electron microscopy and X-ray diffraction Adv. Prot. Chem. 50 1997 123 159
D.R. Booth, M. Sunde, V. Bellotti, C.V. Robinson, W.L. Hutchinson, and P.E. Fraser Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis Nature 385 1997 787 793
W. Colon, and J.W. Kelly Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro Biochemistry 31 1992 8654 8660
J.W. Kelly The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways Curr. Opin. Struct. Biol. 8 1998 101 106
V.N. Uversky, J. Li, and A.L. Fink Evidence for a partially folded intermediate in alpha-synuclein fibril formation J. Biol. Chem. 276 2001 10737 10744
R. Kayed, J. Bernhagen, N. Greenfield, K. Sweimeh, H. Brunner, and W. Voelter Conformational transitions of islet amyloid polypeptide (IAPP) in amyloid formation in vitro J. Mol. Biol. 287 1999 781 796
J.D. Harper, and P.T. Lansbury Jr. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins Annu. Rev. Biochem. 66 1997 385 407
J. Zurdo Polypeptide models to understand protein misfolding and amyloid formation. Applications to protein design and therapeutics Prot. Pept. Lett. 2004 (in press)
L.A. Morozova-Roche, J. Zurdo, A. Spencer, W. Noppe, V. Receveur, and D.B. Archer Amyloid fibril formation and seeding by wild-type human lysozyme and its disease-related mutational variants J. Struct. Biol. 130 2000 339 351
M.R. Krebs, D.K. Wilkins, E.W. Chung, M.C. Pitkeathly, A.K. Chamberlain, and J. Zurdo Formation and seeding of amyloid fibrils from wild-type hen lysozyme and a peptide fragment from the beta-domain J. Mol. Biol. 300 2000 541 549
D. Hamada, and C.M. Dobson A kinetic study of beta-lactoglobulin amyloid fibril formation promoted by urea Prot. Sci. 11 2002 2417 2426
M. Dumoulin, A.M. Last, A. Desmyter, K. Decanniere, D. Canet, G. Larsson, A. Spencer, D.B. Archer, J. Sasse, S. Muyldermans, L. Wyns, C. Redfield, A. Matagne, C.V. Robinson, and C.M. Dobson A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme Nature 424 2003 783 788
Y. Yonezawa, S. Tanaka, T. Kubota, K. Wakabayashi, K. Yutani, and S. Fujiwara An insight into the pathway of the amyloid fibril formation of hen egg white lysozyme obtained from a small-angle X-ray and neutron scattering study J. Mol. Biol. 323 2002 237 251
A.K. Chamberlain, C.E. MacPhee, J. Zurdo, L.A. Morozova-Roche, H.A. Hill, and C.M. Dobson Ultrastructural organization of amyloid fibrils by atomic force microscopy Biophys. J. 79 2000 3282 3293
N.M. Kad, S.L. Myers, D.P. Smith, D.A. Smith, S.E. Radford, and N.H. Thomson Hierarchical assembly of beta2-microglobulin amyloid in vitro revealed by atomic force microscopy J. Mol. Biol. 330 2003 785 7999
M. Bouchard, J. Zurdo, E.J. Nettleton, C.M. Dobson, and C.V. Robinson Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy Prot. Sci. 9 2000 1960 1967
L. Nielsen, S. Frokjaer, J.F. Carpenter, and J. Brange Studies of the structure of insulin fibrils by Fourier transform infrared (FTIR) spectroscopy and electron microscopy J. Pharm. Sci. 90 2001 29 37
J.L. Jimenez, J.I. Guijarro, E. Orlova, J. Zurdo, C.M. Dobson, and M. Sunde Cryo-electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing EMBO J. 18 1999 815 821
J.L. Jimenez, E.J. Nettleton, M. Bouchard, C.V. Robinson, C.M. Dobson, and H.R. Saibil The protofilament structure of insulin amyloid fibrils Proc. Natl. Acad. Sci. USA 99 2002 9196 9201
M. Hoshino, H. Katou, Y. Hagihara, K. Hasegawa, H. Naiki, and Y. Goto Mapping the core of the beta(2)-microglobulin amyloid fibril by H/D exchange Nat. Struct. Biol. 9 2002 332 336
I. Kheterpal, H.A. Lashuel, D.M. Hartley, T. Walz, P.T. Lansbury Jr., and R. Wetzel Abeta protofibrils possess a stable core structure resistant to hydrogen exchange Biochemistry 42 2003 14092 14098
I. Kheterpal, S. Zhou, K.D. Cook, and R. Wetzel Abeta amyloid fibrils possess a core structure highly resistant to hydrogen exchange Proc. Natl. Acad. Sci. USA 97 2000 13597 13601
A. Olofsson, J.H. Ippel, S.S. Wijmenga, E. Lundgren, and A. Ohman Probing solvent accessibility of transthyretin amyloid by solution NMR spectroscopy J. Biol. Chem. 279 2004 5699 5707
P.T. Lansbury Jr., P.R. Costa, J.M. Griffiths, E.J. Simon, M. Auger, and K.J. Halverson Structural model for the beta-amyloid fibril based on interstrand alignment of an antiparallel-sheet comprising a C-terminal peptide Nat. Struct. Biol. 2 1995 990 998
A.T. Petkova, G. Buntkowsky, F. Dyda, R.D. Leapman, W.M. Yau, and R. Tycko Solid state NMR reveals a pH-dependent antiparallel beta-sheet registry in fibrils formed by a beta-amyloid peptide J. Mol. Biol. 335 2004 247 260
P. Polverino de Laureto, N. Taddei, E. Frare, C. Capanni, S. Costantini, J. Zurdo, F. Chiti, C.M. Dobson, and A. Fontana Protein aggregation and amyloid fibril formation by an SH3 domain probed by limited proteolysis J. Mol. Biol. 334 2003 129 141
M. Monti, B.L. Garolla di Bard, G. Calloni, F. Chiti, A. Amoresano, G. Ramponi, and P. Pucci The regions of the sequence most exposed to the solvent within the amyloidogenic state of a protein initiate the aggregation process J. Mol. Biol. 336 2004 253 262
F. Chiti, N. Taddei, M. Bucciantini, P. White, G. Ramponi, and C.M. Dobson Mutational analysis of the propensity for amyloid formation by a globular protein EMBO J. 19 2000 1441 1449
T. Chiba, Y. Hagihara, T. Higurashi, K. Hasegawa, H. Naiki, and Y. Goto Amyloid fibril formation in the context of full-length protein: effects of proline mutations on the amyloid fibril formation of beta2-microglobulin J. Biol. Chem. 278 2003 47016 47024
A.D. Williams, E. Portelius, I. Kheterpal, J.T. Guo, K.D. Cook, Y. Xu, and R. Wetzel Mapping abeta amyloid fibril secondary structure using scanning proline mutagenesis J. Mol. Biol. 335 2004 833 842
F. Eghiaian, J. Grosclaude, S. Lesceu, P. Debey, B. Doublet, E. Treguer, H. Rezaei, and M. Knossow Insight into the PrP C → PrP Sc conversion from the structures of antibody-bound ovine prion scrapie-susceptibility variants Proc. Natl. Acad. Sci. USA 101 2004 10254 10259
M. Venturi, and C. Hunte Monoclonal antibodies for the structural analysis of the Na +/H + antiporter NhaA from Escherichia coli Biochim. Biophys. Acta 1610 2003 46 50
R. Loris, I. Marianovsky, J. Lah, T. Laeremans, H. Engelberg-Kulka, G. Glaser, S. Muyldermans, and L. Wyns Crystal structure of the intrinsically flexible addiction antidote MazE J. Biol. Chem. 278 2003 28252 28257
C. Ostermeier, S. Iwata, B. Ludwig, and H. Michel Fv fragment-mediated crystallization of the membrane protein bacterial cytochrome c oxidase Nat. Struct. Biol. 2 1995 842 846
G. Goldsteins, H. Persson, K. Andersson, A. Olofsson, I. Dacklin, and A. Edvinsson Exposure of cryptic epitopes on transthyretin only in amyloid and in amyloidogenic mutants Proc. Natl. Acad. Sci. USA 96 1999 3108 3113
V. Curin Serbec, M. Bresjanac, M. Popovic, K. Pretnar Hartman, V. Galvani, R. Rupreht, M. Cernilec, T. Vranac, I. Hafner, and R. Jerala Monoclonal antibody against a peptide of human prion protein discriminates between Creutzfeldt-Jacob's disease-affected and normal brain tissue J. Biol. Chem. 279 2004 3694 3698
E. Paramithiotis, M. Pinard, T. Lawton, S. LaBoissiere, V.L. Leathers, W.Q. Zou, L.A. Estey, J. Lamontagne, M.T. Lehto, L.H. Kondejewski, G.P. Francoeur, M. Papadopoulos, A. Haghighat, S.J. Spatz, M. Head, R. Will, J. Ironside, K. O'Rourke, Q. Tonelli, H.C. Ledebur, A. Chakrabartty, and N.R. Cashman A prion protein epitope selective for the pathologically misfolded conformation Nat. Med. 9 2003 893 899
R.A. Williamson, D. Peretz, C. Pinilla, H. Ball, R.B. Bastidas, and R. Rozenshteyn Mapping the prion protein using recombinant antibodies J. Virol. 72 1998 9413 9418
D. Peretz, R.A. Williamson, Y. Matsunaga, H. Serban, C. Pinilla, and R.B. Bastidas A conformational transition at the N terminus of the prion protein features in formation of the scrapie isoform J. Mol. Biol. 273 1997 614 622
Y. Matsunaga, D. Peretz, A. Williamson, D. Burton, I. Mehlhorn, D. Groth, F.E. Cohen, S.B. Prusiner, and M.A. Baldwin Cryptic epitopes in N-terminally truncated prion protein are exposed in the full-length molecule: dependence of conformation on pH Proteins 44 2001 110 118
Z.F. Kanyo, K.M. Pan, R.A. Williamson, D.R. Burton, S.B. Prusiner, and R.J. Fletterick Antibody binding defines a structure for an epitope that participates in the PrP C → PrP Sc conformational change J. Mol. Biol. 293 1999 855 863
E. Leclerc, D. Peretz, H. Ball, L. Solforosi, G. Legname, J. Safar, A. Serban, S.B. Prusiner, D.R. Burton, and R.A. Williamson Conformation of PrP C on the cell surface as probed by antibodies J. Mol. Biol. 326 2003 475 483
D.M. Walsh, I. Klyubin, J.V. Fadeeva, M.J. Rowan, and D.J. Selkoe Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition Biochem. Soc. Trans. 30 2002 552 557
W.L. Klein Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets Neurochem. Int. 41 2002 345 352
R. Kayed, E. Head, J.L. Thompson, T.M. McIntire, S.C. Milton, C.W. Cotman, and C.G. Glabe Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis Science 300 2003 486 489
P. Mangione, M. Sunde, S. Giorgetti, M. Stoppini, G. Esposito, L. Gianelli, L. Obici, L. Asti, A. Andreola, P. Viglino, G. Merlini, and V. Bellotti Amyloid fibrils derived from the apoliprotein A1 Leu74Ser variant contain elements of ordered helical structure Prot. Sci. 10 2001 187 199
C.P. Jaroniec, C.E. MacPhee, V.S. Bajaj, M.T. McMahon, C.M. Dobson, and R.G. Griffin High-resolution molecular structure of a peptide in an amyloid fibril determined by magic angle spinning NMR spectroscopy Proc. Natl. Acad. Sci. USA 101 2004 711 716
B. Solomon, R. Koppel, E. Hanan, and T. Katzav Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide Proc. Natl. Acad. Sci. USA 93 1996 452 455
B. Solomon, R. Koppel, D. Frankel, and E. Hanan-Aharon Disaggregation of Alzheimer beta-amyloid by site-directed mAb Proc. Natl. Acad. Sci. USA 94 1997 4109 4112
D. Frenkel, O. Katz, and B. Solomon Immunization against Alzheimer's beta-amyloid plaques via EFRH phage administration Proc. Natl. Acad. Sci. USA 97 2000 11455 11459
J. McLaurin, R. Cecal, M.E. Kierstead, X. Tian, A.L. Phinney, M. Manea, J.E. French, M.H. Lambermon, A.A. Darabie, M.E. Brown, C. Janus, M.A. Chishti, P. Horne, D. Westaway, P.E. Fraser, H.T. Mount, M. Przybylski, and P. St George-Hyslop Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis Nat. Med. 8 2002 1263 1269
A.T. Petkova, Y. Ishii, J.J. Balbach, O.N. Antzutkin, R.D. Leapman, F. Delaglio, and R. Tycko A structural model for Alzheimer's beta-amyloid fibrils based on experimental constraints from solid state NMR Proc. Natl. Acad. Sci. USA 99 2002 16742 16747
S. Emadi, R. Liu, B. Yuan, P. Schulz, C. McAllister, Y. Lyubchenko, A. Messer, and M.R. Sierks Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments Biochemistry 43 2004 2871 2878
B. O'Nuallain, and R. Wetzel Conformational Abs recognizing a generic amyloid fibril epitope Proc. Natl. Acad. Sci. USA 99 2002 1485 1490
R. Hrncic, J. Wall, D.A. Wolfenbarger, C.L. Murphy, M. Schell, and D.T. Weiss Antibody-mediated resolution of light chain-associated amyloid deposits Am. J. Pathol. 157 2000 1239 1246
D. Thompson, M.B. Pepys, I. Tickle, and S. Wood The structures of crystalline complexes of human serum amyloid P component with its carbohydrate ligand, the cyclic pyruvate acetal of galactose J. Mol. Biol. 320 2002 1081 1086
M. Przybylski, V. Schnaible, J. Kast, S. Bohler, J. Michels, and A. Wattenberg Approaches to the characterisation of tertiary and supramolecular protein structures by combination of protein chemistry and mass spectrometry W. Ens New Methods for the Study of Biomolecular Complexes 1998 Kluwer Academic Publishers Amsterdam 17 43
E. Hanan, O. Goren, M. Eshkenazy, and B. Solomon Immunomodulation of the human prion peptide 106-126 aggregation Biochem. Biophys. Res. Commun. 280 2001 115 120
C.M. Dobson Protein misfolding, evolution and disease Trends Biochem. Sci. 24 1999 329 332
D. Peretz, R.A. Williamson, K. Kaneko, J. Vergara, E. Leclerc, G. Schmitt-Ulms, I.R. Mehlhorn, G. Legname, M.R. Wormald, P.M. Rudd, R.A. Dwek, D.R. Burton, and S.B. Prusiner Antibodies inhibit prion propagation and clear cell cultures of prion infectivity Nature 412 2001 739 743
M.P. Lambert, K.L. Viola, B.A. Chromy, L. Chang, T.E. Morgan, J. Yu, D.L. Venton, G.A. Krafft, C.E. Finch, and W.L. Klein Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies J. Neurochem. 79 2001 595 605
Y. Gong, L. Chang, K.L. Viola, P.N. Lacor, M.P. Lambert, C.E. Finch, G.A. Krafft, and W.L. Klein Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss Proc. Natl. Acad. Sci. USA 100 2003 10417 10422
D. Morgan, D.M. Diamond, P.E. Gottschall, K.E. Ugen, C. Dickey, and J. Hardy A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease Nature 408 2000 982 985
J.C. Dodart, K.R. Bales, K.S. Gannon, S.J. Greene, R.B. DeMattos, C. Mathis, C.A. DeLong, S. Wu, X. Wu, D.M. Holtzman, and S.M. Paul Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model Nat. Neurosci. 5 2002 452 457
E. Kubler, B. Oesch, and A.J. Raeber Diagnosis of prion diseases Br. Med. Bull. 66 2003 267 279
A.F. Hill, M. Zeidler, J. Ironside, and J. Collinge Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy Lancet 349 1997 99 100
B.E. Schreuder, L.J. Van Keulen, M.E. Vromans, J.P. Langeveld, and M.A. Smits Tonsillar biopsy and PrP Sc detection in the preclinical diagnosis of scrapie Vet. Rec. 142 1998 564 568
D.A. Hilton, E. Fathers, P. Edwards, J.W. Ironside, and J. Zajicek Prion immunureactivity in appendix before clinical onset of variant Creutzfeldt-Jacob disease Lancet 352 1998 703 704
R.B. DeMattos, K.R. Bales, D.J. Cummins, S.M. Paul, and D.M. Holtzman Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease Science 295 2002 2264 2267
F. Bard, C. Cannon, R. Barbour, R.L. Burke, D. Games, and H. Grajeda Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat. Med. 6 2000 916 919
F. Bard, R. Barbour, C. Cannon, R. Carretto, M. Fox, D. Games, T. Guido, K. Hoenow, K. Hu, K. Johnson-Wood, K. Khan, D. Kholodenko, C. Lee, M. Lee, R. Motter, M. Nguyen, A. Reed, D. Schenk, P. Tang, N. Vasquez, P. Seubert, and T. Yednock Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology Proc. Natl. Acad. Sci. USA 100 2003 2023 2028
D. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, and T. Guido Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse Nature 400 1999 173 177
C. Janus, J. Pearson, J. McLaurin, P.M. Mathews, Y. Jiang, and S.D. Schmidt A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease Nature 408 2000 979 982
D.M. Wilcock, A. Rojiani, A. Rosenthal, G. Levkowitz, S. Subbarao, J. Alamed, D. Wilson, N. Wilson, M.J. Freeman, M.N. Gordon, and D. Morgan Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition J. Neurosci. 24 2004 6144 6151
F.L. Heppner, C. Musahl, I. Arrighi, M.A. Klein, T. Rulicke, B. Oesch, R.M. Zinkernagel, U. Kalinke, and A. Aguzzi Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies Science 294 2001 178 182
E.M. Sigurdsson, D.R. Brown, M. Daniels, R.J. Kascsak, R. Kascsak, R. Carp, H.C. Meeker, B. Frangione, and T. Wisniewski Immunization delays the onset of prion disease in mice Am. J. Pathol. 161 2002 13 17
A.R. White, P. Enever, M. Tayebi, R. Mushens, J. Linehan, S. Brandner, D. Anstee, J. Collinge, and S. Hawke Monoclonal antibodies inhibit prion replication and delay the development of prion disease Nature 422 2003 80 83
D. Schenk Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning Nat. Rev. Neurosci. 3 2002 824 828
J.C. Dodart, K.R. Bales, and S.M. Paul Immunotherapy for Alzheimer's disease: will vaccination work? Trends Mol. Med. 9 2003 85 87
R.C. Dodel, H. Hampel, and H. Du Immunotherapy for Alzheimer's disease Lancet Neurol. 2 2003 215 220
E.M. Sigurdsson, T. Wisniewski, and B. Frangione A safer vaccine for Alzheimer's disease? Neurobiol. Aging 23 2002 1001 1008
A.R. White, and S.H. Hawke Immunotherapy as a therapeutic treatment for neurodegenerative disorders J. Neurochem. 87 2003 801 808
D.S. Gelinas, K. DaSilva, D. Fenili, P. St. George Hyslop, and J. McLaurin Immunotherapy for Alzheimer's disease Proc. Natl. Acad. Sci. USA 101 Suppl. 2 2004 14657 14662
C. Hock, U. Konietzko, J.R. Streffer, J. Tracy, A. Signorell, B. Muller-Tillmanns, U. Lemke, K. Henke, E. Moritz, E. Garcia, M.A. Wollmer, D. Umbricht, D.J. de Quervain, M. Hofmann, A. Maddalena, A. Papassotiropoulos, and R.M. Nitsch Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease Neuron 38 2003 547 554
E. Check Nerve inflamation halts trial for Alzheimer's drug Nature 415 2002 462
L. Solforosi, J.R. Criado, D.B. McGavern, S. Wirz, M. Sanchez-Alvarez, S. Sugama, L.A. DeGiorgio, B.T. Volpe, E. Wiseman, E. Masliah, D. Gilden, M.B. Oldstone, B. Conti, and R.A. Williamson Cross-linking cellular prion protein triggers neuronal apoptosis in vivo Science 303 2004 1514 1516
M. Pfeifer, S. Boncristiano, L. Bondolfi, A. Stalder, T. Deller, M. Staufenbiel, P.M. Mathews, and M. Jucker Cerebral hemorrhage after passive anti-Abeta immunotherapy Science 298 2002 1379
S.M. Greenberg, B.J. Bacskai, and B.T. Hyman Alzheimer diseases double-edged vaccine Nat. Med. 9 2003 389 390
A. Monsonego, and H.L. Weiner Immunotherapeutic approaches to Alzheimer's disease Science 302 2003 834 838
C. Monnet, D. Laune, J. Laroche-Traineau, M. Biard-Piechaczyk, L. Briant, and C. Bes Synthetic peptides derived from the variable regions of an anti-CD4 monoclonal antibody bind to CD4 and inhibit HIV-1 promoter activation in virus-infected cells J. Biol. Chem. 274 1999 3789 3796
P. Amstutz, P. Forrer, C. Zahnd, and A. Pluckthun In vitro display technologies: novel developments and applications Curr. Opin. Biotechnol. 12 2001 400 405
D. Degl'Innocenti, N. Taddei, M. Ramazzotti, M. Stefani, F. Chiti, and G. Ramponi Selection of antibody fragments specific for an alpha-helix region of acylphosphatase J. Mol. Recognit. 17 2004 62 66
B. Bose, D.A. Chugh, M. Kala, S.K. Acharya, N. Khanna, and S. Sinha Characterization and molecular modeling of a highly stable anti-Hepatitis B surface antigen scFv Mol. Immunol. 40 2003 617 631
C. Hamers-Casterman, T. Atarhouch, S. Muyldermans, G. Robinson, C. Hamers, and E.B. Songa Naturally occurring antibodies devoid of light chains Nature 363 1993 446 448
S. Muyldermans Single domain camel antibodies: current status J. Biotechnol. 74 2001 277 302
M. Dumoulin, K. Conrath, A. Van Meirhaeghe, F. Meersman, K. Heremans, L.G. Frenken, S. Muyldermans, L. Wyns, and A. Matagne Single-domain antibody fragments with high conformational stability Prot. Sci. 11 2002 500 515
A. Muruganandam, J. Tanha, S. Narang, and D. Stanimirovic Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium FASEB J. 16 2002 240 242
M.B. Pepys, P.N. Hawkins, D.R. Booth, D.M. Vigushin, G.A. Tennent, and A.K. Soutar Human lysozyme gene mutations cause hereditary systemic amyloidosis Nature 362 1993 553 557
S. Valleix, S. Drunat, J.B. Philit, D. Adoue, J.C. Piette, D. Droz, B. MacGregor, D. Canet, M. Delpech, and G. Grateau Hereditary renal amyloidosis caused by a new variant lysozyme W64R in a French family Kidney Int. 61 2002 907 912
M. Yazaki, S.A. Farrell, and M.D. Benson A novel lysozyme mutation Phe57Ile associated with hereditary renal amyloidosis Kidney Int. 63 2003 1652 1657
D. Canet, A.M. Last, P. Tito, M. Sunde, A. Spencer, D.B. Archer, C. Redfield, C.V. Robinson, and C.M. Dobson Local cooperativity in the unfolding of an amyloidogenic variant of human lysozyme Nat. Struct. Biol. 9 2002 308 315
A.K. Chamberlain, V. Receveur, A. Spencer, C. Redfield, and C.M. Dobson Characterization of the structure and dynamics of amyloidogenic variants of human lysozyme by NMR spectroscopy Prot. Sci. 10 2001 2525 2530